Alembic Pharmaceuticals Ltd Q4 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- U.S. business expected to grow at mid to high teens (around 15%) in FY'26, driven by new product launches and volume growth.
- Rest of the World (ROW) business projected to grow between 12% to 15% in FY'26.
- API business anticipated to grow around 10% in FY'26.
- Indian business is positive about achieving double-digit growth (10%+) for FY'26, despite past challenges in anti-infective segment.
- Stable number of Medical Representatives (~5,500) with minor additions (~100) expected, indicating continuation of current sales efforts.
- Animal Health business continues strong growth (19% quarterly, 21% annually) with robust product portfolio and new launches.
- Ongoing efforts to optimize costs, improve utilization, and maintain R&D focus to support growth.
- U.S. launches pipeline remains robust with 15+ planned in FY'26, with about 20%-30% considered high-value, less competition products.
See what Alembic Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned new fundraising through debt or equity in the call.
- As of the latest update, borrowings stand at Rs. 1,196 crore with a healthy debt-to-equity ratio of 0.23.
- Short-term borrowings have increased due to higher working capital requirements but the company aims to reduce borrowings through cash flow and working capital release in FY'26.
- No indication of plans for equity issuance.
- CAPEX is expected to be around Rs. 400-450 crores for maintenance and completing existing projects, with no significant large new CAPEX projects planned.
- R&D spend is forecasted to be Rs. 600-650 crores, funded from internal resources.
- Overall, the company appears focused on optimizing existing resources and cash flow rather than raising fresh funds via debt or equity.
See what Alembic Pharmaceuticals Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Major CAPEX projects for FY'25 included commissioning the Pithampur manufacturing facility, building a new peptide block for peptide manufacturing at API 2, and adding an additional injectable line at F3.
- These major projects are now over.
- Maintenance and regular CAPEX going forward is budgeted around Rs. 400-450 crores for FY'26, including some spillover expenses from existing projects.
- No significant new large CAPEX projects are expected in FY'26.
- Peptide block manufacturing is part of the CAPEX for strategic investment in complex injectables.
- Focus remains on augmenting manufacturing capacity, improved logistics, and targeted R&D investment (guidance Rs. 600-650 crores for FY'26).
- Past investments aim at increasing facility utilization and enabling operating leverage over the next few years.
Track Alembic Pharmaceuticals Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- U.S. business expected to grow mid to high teens (~15%) in FY'26, driven by new product launches and volume growth.
- Rest of World (ROW) business projected to grow between 12%-15%.
- API business anticipated growth of about 10%.
- India business optimistic for double-digit growth (~10%+) after recent market moderation.
- EBITDA margins targeted to improve over the next couple of years due to better facility utilization and cost optimization efforts.
- Operating leverage expected from new manufacturing facilities (especially injectables) coming on stream.
- R&D investment to increase to Rs. 600-650 crores in FY'26, supporting future product pipeline and growth.
- EPS growth correlating with revenue and margin improvements, though no specific number was provided.
- Overall, management confident of sustainable profit growth driven by multiple growth levers including launches, operational efficiencies, and market recovery.
Order book
How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…